» Articles » PMID: 36558417

Hypomagnesemia and the Metabolic Syndrome Among Apparently Healthy Kuwaiti Adults: A Cross-Sectional Study

Overview
Journal Nutrients
Date 2022 Dec 23
PMID 36558417
Authors
Affiliations
Soon will be listed here.
Abstract

Magnesium plays a key role in metabolic disorder development, and hypomagnesemia may be implicated in the pathogenesis of metabolic syndrome (MetS) and its components. In this cross-sectional study, we investigated the associations between hypomagnesemia, MetS, and MetS components among 231 adults (193 women and 38 men) living in Kuwait who were apparently healthy without chronic diseases. We used the International Diabetes Federation (IDF) and the United States National Cholesterol Education Program Adult Treatment Panel III (ATP III) criteria to define participants with MetS. The Ministry of Health cutoff for hypomagnesemia (<0.74 mmol/L) was employed. IDF- and ATP III-defined MetS prevalence was 22.1% and 15.2%, respectively. Hypomagnesemia occurred in 33.3% of all participants and 53.2% of participants with MetS (p < 0.001). Magnesemia correlated negatively with body mass index, waist circumference, systolic blood pressure [SBP], diastolic blood pressure (DBP), fasting blood glucose (FBG), low-density lipoprotein cholesterol level, and triglyceride level; magnesemia correlated positively with high-density lipoprotein cholesterol (HDL-C) levels (p < 0.001). Multivariate logistic regression, adjusting for BMI, age, and sex, showed that hypomagnesemia was associated with a 12- and 5-fold greater odds of getting IDF-defined (adjusted odds ratio [aOR] 11.70; 95% confidence interval [CI] 4.87−28.14) and ATP-defined (aOR 5.44; 95% CI 2.10−14.10) MetS, respectively, in the study population. Hypomagnesemia was significantly associated with a 3.62, 9.29, 7.01, 2.88, 3.64, and 3.27 higher odds of an increased waist circumference (95% CI 1.48−8.85), elevated serum triglyceride level (95% CI 3.97−21.73), elevated FBG (95% CI 3.25−15.11), elevated SBP (95% CI 1.16−7.11), elevated DBP (95% CI: 1.22−10.89), and lowered HDL-C level (95% CI 1.69−6.32), respectively. Hypomagnesemia could be a consequence of the pathophysiology of MetS and its individual components among adults in Kuwait.

Citing Articles

Low dietary magnesium and fiber intakes among women with metabolic syndrome in Kuwait.

Alkazemi D, Zafar T, Alsouri N, Aljahdali A, Kubow S Front Nutr. 2024; 11:1451220.

PMID: 39479191 PMC: 11521934. DOI: 10.3389/fnut.2024.1451220.


Diet, lifestyle factors, comorbidities, and hepatocellular carcinoma risk in a middle eastern country: a case-control study.

Almohaid S, Akhtar S BMC Cancer. 2024; 24(1):694.

PMID: 38844890 PMC: 11157712. DOI: 10.1186/s12885-024-12409-0.


Plasma Levels of Magnesium, Calcium, Calcium to Magnesium Ratio, and Associations with Metabolic Syndrome and Cardiometabolic Risk Factors.

Moia M, Lima S, da Silva Nunes F, Queiroz S, Marchioni D, Pedrosa L Biol Trace Elem Res. 2024; 202(12):5307-5318.

PMID: 38347294 DOI: 10.1007/s12011-024-04088-6.


Association between Serum Magnesium Levels and Risk of Dyslipidemia: A Cross-Sectional Study from the China Health and Nutrition Survey.

Liu Y, Li S Biol Trace Elem Res. 2023; 202(6):2410-2418.

PMID: 37688672 DOI: 10.1007/s12011-023-03846-2.


The Link between Magnesium Supplements and Statin Medication in Dyslipidemic Patients.

Nartea R, Mitoiu B, Ghiorghiu I Curr Issues Mol Biol. 2023; 45(4):3146-3167.

PMID: 37185729 PMC: 10136538. DOI: 10.3390/cimb45040205.

References
1.
Costello R, Elin R, Rosanoff A, Wallace T, Guerrero-Romero F, Hruby A . Perspective: The Case for an Evidence-Based Reference Interval for Serum Magnesium: The Time Has Come. Adv Nutr. 2017; 7(6):977-993. PMC: 5105038. DOI: 10.3945/an.116.012765. View

2.
Al Zenki S, Al Omirah H, Al Hooti S, Al Hamad N, Jackson R, Rao A . High prevalence of metabolic syndrome among Kuwaiti adults--a wake-up call for public health intervention. Int J Environ Res Public Health. 2012; 9(5):1984-96. PMC: 3386600. DOI: 10.3390/ijerph9051984. View

3.
Piuri G, Zocchi M, Porta M, Ficara V, Manoni M, Zuccotti G . Magnesium in Obesity, Metabolic Syndrome, and Type 2 Diabetes. Nutrients. 2021; 13(2). PMC: 7912442. DOI: 10.3390/nu13020320. View

4.
Jung U, Choi M . Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci. 2014; 15(4):6184-223. PMC: 4013623. DOI: 10.3390/ijms15046184. View

5.
Ridker P, Buring J, Cook N, Rifai N . C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003; 107(3):391-7. DOI: 10.1161/01.cir.0000055014.62083.05. View